Quantcast

Latest Blood glucose monitoring Stories

2014-05-01 08:37:03

Critical intellectual property recognition is a major step in bringing Dario(TM) to market in the U.S. CAESAREA, Israel, May 1, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the company's personalized blood glucose monitoring device. LabStyle's now patent pending invention,...

2014-04-28 08:33:10

600,000 Italians Now Eligible for Reimbursement Coverage CAESAREA, Israel, April 28, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has received national approval and regional reimbursement for the Dario(TM) Personalized Smart Meter in Italy. Receipt of reimbursement approvals is a key component of LabStyle's continuing commercial roll out of the Dario(TM) Diabetes Management Solution....

2014-04-28 08:31:53

Pivotal Trial to Build on Previous Positive Studies; Aims to Further Demonstrate Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System in the ICU HAYWARD, Calif., April 28, 2014 /PRNewswire/ -- OptiScan Biomedical Corporation, a developer of innovative continuous monitoring systems for use in the intensive care unit (ICU), today announced the enrollment of the first patient in a pivotal, multi-center Investigational Device Exemption (IDE) clinical study of the...

2014-04-25 08:26:55

DUBLIN, April 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zvrjkt/selfcare_medical) have announced the addition of the "Self-Care Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/zvrjkt/selfcare_medical ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Self-care medical devices are...

2014-04-24 16:28:58

ORMD-0801 Oral Insulin Appeared Safe and Well-tolerated. No Hypoglycemic Events or Treatment Related Adverse Events Observed JERUSALEM, April 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2...

2014-04-24 12:28:58

PORTLAND, Oregon, April 24, 2014 /PRNewswire/ -- The database of Research Beam has a latest addition of report, titled "Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 -2020." This report prepared with insightful analysis provides a microscopic view about continuous glucose monitoring market to...

2014-04-24 12:28:52

PORTLAND, Oregon, April 24, 2014 /PRNewswire/ -- Wound closure and advanced wound care products are gaining ground over traditional methods of wound care, globally. Factors propelling the advanced wound care products are the minimal need of bed capacity in hospitals, and shifting inclination towards homecare therapies that enhance healing and minimize hospital time. Therapies and products that promote faster wound healing are gaining prominence due to the recovery time taken...

2014-04-23 23:09:58

Live webinar to focus on the development of a novel telemetry device for continuous monitoring of glucose in rodents. The broadcast takes place on Tuesday, May 13, 2014 at 11:00am EDT (16:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) April 23, 2014 Glucose monitoring options for preclinical research have historically been limited when compared to the options available for human monitoring. As an example, Continuous Glucose Monitors (CGMs) have been prevalent in human medical applications...

2014-04-14 12:34:30

New Abbott test could help physicians diagnose people in the U.S. who are unaware that they have diabetes, empowering them to control their disease ABBOTT PARK, Ill., April 14, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test - which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease - has received 510(k) clearance from the U.S. Food and Drug...

2014-04-14 12:32:44

Conference Call and Webcast at 8:30 a.m. Eastern Time THE WOODLANDS, Texas, April 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'